Home › Trial NCT05112536
Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer
- Trial IDNCT05112536
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorG1 Therapeutics, Inc.
- Enrollment24
- Start date2022-03-03
- ConditionsTriple Negative Breast Cancer · Breast Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.